| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Puma Biotechnology, Inc. (PBYI) has 5 insiders with recent SEC Form 4 filings, including 0 buys and 38 sells. PBYI is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 227.5K | $1.81M | - | |
| Other | 70.3K | $559.1K | - | |
| CFO | 66.5K | $529.0K | - | |
| Dir | 54.0K | $429.3K | - | |
| Dir | 41.9K | $332.7K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Jul 3, 2017 | Bryce Richard Paul | Sr VP, Clinical Research &Dev | Sale+OE | 5,000 | $87.10 | $435,500.00 | -14.6% | |
| Jun 12, 2017 | Adage Capital Partners Gp, L.l.c.64 | 10% Owner | Sell | 247,260 | $80.32 | $19,858,909.96 | -1.1% | |
| Jun 5, 2017 | Adage Capital Partners Gp, L.l.c.64 | 10% Owner | Sell | 507,128 | $87.84 | $44,544,975.45 | -1.2% | |
| May 26, 2017 | Adage Capital Partners Gp, L.l.c.64 | 10% Owner | Sell | 1,235,700 | $75.38 | $93,144,267.69 | -1.7% | |
| Feb 1, 2017 | Charnas Robert | See Remarks | Sell | 3,008 | $31.83 | $95,754.80 | -5.2% | |
| Jan 20, 2017 | Lo Steven | Chief Commercial Officer | Sell | 2,290 | $33.24 | $76,108.38 | -7.3% | |
| Jan 20, 2017 | Eyler Charles R | See Remarks | Sell | 820 | $33.24 | $27,252.78 | -7.8% | |
| Jan 20, 2017 | Bryce Richard Paul | Sr VP, Clinical Research &Dev | Sell | 2,293 | $33.24 | $76,208.08 | -7.3% | |
| Jan 20, 2017 | Auerbach Alan H62 | President And CEO | Sell | 10,202 | $33.24 | $339,064.49 | -0.2% | |
| Jan 20, 2017 | Charnas Robert | See Remarks | Sell | 2,293 | $33.24 | $76,208.08 | -7.2% |